AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00867841 — intervention group
Intervention type: PROCEDURE
Intervention: nasopharyngeal swab
Description: PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
Study NCT04955366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg monthly
Study NCT04955366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Abatacept is an immunosuppressive medication and will be given SQ at a dose of 125 mg s.c. weekly
Study NCT06570304 — intervention group
Intervention type: PROCEDURE
Intervention: iCount Device
Description: Designed as single use. Intended purpose - To be used to count swabs and tampons after surgery in an objective manner. This is intended to be used in patients during and just after surgery.~This is a device accessory.
Study NCT04689568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moodkit
Description: MoodKit is divided into four main sections: Activities, Thoughts, Mood and Journal. In the Thoughts section, the user is asked to briefly describe stressful situations and their reactions to the event and is later educated on a number of thought distortions. In the Mood section, the user is asked to give an overall rating of mood, which can be done several times per day. In the Journal section, the user can write freestanding journal entries. Additional areas of advice and goal setting are contained in a section called Thrive Tips.
Study NCT04328389 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: electric toothbrush
Description: Participants will be instructed to use their electric toothbrushes twice a day for controlling oral plaque
Study NCT04328389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Professional oral hygiene
Description: Professional oral hygiene using ultrosound scaling and root planing
Study NCT04629430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-biotic foods/drinks
Description: 2 servings per day
Study NCT04689568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moodgym
Description: The program consists of five modules each taking 20- to 40-minutes to complete, which are completed in a prescribed order.
Study NCT04689568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: University of Michigan Depression Center Toolkit
Description: The Toolkit provides information, tools, support, and resources to guide individuals through their mental health journey.
Study NCT04855513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is a medication used for treatment of diabetes. In this study it will be used to explore is potential role in prevention of preeclampsia. The drug will start before 12 week of pregnancy and continue till delivery
Study NCT06357923 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: dosage
Description: Presence of mutation on the gene panel and Frequency of allele variation
Study NCT06471309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst transcranial magnetic stimulation
Description: The stimulation intensity of TBS was 80%RMT, with a total of 600 pulses, five times a week for two weeks. In the bilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the unilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the sham stimulation group, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. When giving sham stimulation, put the coil vertically so that the coil is perpendicular to the patient's skull surface , it will not produce real therapeutic effect.
Study NCT06471309 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta burst transcranial magnetic stimulation
Description: The stimulation intensity of TBS was 80%RMT, with a total of 600 pulses, five times a week for two weeks. In the bilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the unilateral stimulation group, iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. In the sham stimulation group, sham iTBS treatment was given to the representative area of mylohyoid cortex on the affected side and sham cTBS treatment was given to the representative area of mylohyoid cortex on the healthy side. When giving sham stimulation, put the coil vertically so that the coil is perpendicular to the patient's skull surface , it will not produce real therapeutic effect.
Study NCT05943821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 200 mg
Description: The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
Study NCT05943821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allopurinol 200 mg
Description: The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
Study NCT05943821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optional intervention
Description: Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels >5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up.
Study NCT05943821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Optional intervention
Description: Approximately 26 weeks(+/-2 weeks) after the start of the intervention, the efficacy of the treatment will be evaluated at the follow-up visit V2. Efficacy is defined as achieving a serum UA level below 5.0mg/dL for those with baseline levels >5.0 to 7.0mg/dL or below 5.5mg/dL for those with baseline levels ≥7.0mg/dL. If insufficient therapy efficacy is noted, the initial allopurinol dose will be increased by 100mg (up to 300mg during V2). The dose may be increased by another 100mg at visit 3 and by another 100mg at the visit 4(up to 500mg during V4). In the placebo group, an appropriate preparation will be added so that the number of tablets corresponds to the group with the active substance.~This treatment will be continued until the end of the bservation. Patients who meet their UA target concentration at visit V2 or V3, or V4, and those who fail to meet their target concentration at visit V4, will not have their dosing changed until the end of the follow-up.
Study NCT06109194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint mobilization
Description: Grade III manual joint mobilization as standard-of-care physical therapy intervention
Study NCT04826003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7122290
Description: RO7122290 will be administered using a QW (Part I) or Q3W (Part I or Part II) schedule in combination with 100 mg cibisatamab Q3W with obinutuzumab pre-treatment. The maximum dose of RO7122290 to be explored in combination with cibisatamab with obinutuzumab pre-treatment in this study is 500 mg for the QW dosing interval (Part I) or 1500 mg for the Q3W dosing interval (Part I or Part II).
Study NCT04826003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cibisatamab
Description: Cibisatamab will be administered to participants at a fixed dose of 100 mg Q3W (100 mg on Day 1 of each 21-day cycle).
Study NCT04826003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered (IV) as pre-treatment on Day - 8/- 7 (split dose) or~- 8 (single dose) prior to C1D1 of cibisatamab and as re-treatment every 6 months if the participant is still receiving cibisatamab
Study NCT04709783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Step Workout for Life
Description: Participants will receive the modified 3-step Workout for Life program given by their physical therapy or occupational therapy providers. The program includes single-joint and multiple joint progressive resistance exercise and activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and/or lower extremity. During the activities of daily living exercise, participants will practice activities of daily living that they experience difficulty. The intervention volume, duration, and frequency will be modified to enhance practicality in a home health care setting over the implementation phase. In addition to the 3-Step Workout for Life exercise, participants may also receive other routine rehabilitation treatment determined and provided by their therapists to facilitate their functional recovery.
Study NCT05386095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.25%Bupivacaine Axillary brachial plexus block
Description: Axillary brachial plexus block will be induced with patient in supine position under GA with the linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle .The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.25% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
Study NCT05386095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.19% Bupivacaine Axillary brachial plexus block
Description: Axillary brachial plexus block will be induced with patient in supine position under GA with linear probe ultrasound , the operating arm will be abducted by 70 , externally rotated, and the elbow will be flexed to \~90. Within the axillary crease the probe will be placed in sagittal position bounded by the pectoralis major antero-medially and the latissimus dorsi and teres major posteromedial. The median nerve lies between 9 and 12 o'clock position above the axillary artery and below the biceps muscle; (ii) the ulnar nerve located superficially between the axillary vein and artery (iii) the radial nerve lies above the conjoint tendon of the teres major and latissimus dorsi (iiii) The musculocutaneous nerve lies between biceps and coracobrachialis muscle.The block will be applied by 22 gag needles at cephalic side of the probe. A total volume of (0.5ml/kg) of 0.19% Bupivacaine plus 1 µg/kg dexmedetomidine will be used.this volume will be divided equally among the four nerves.
Study NCT05960032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant
Description: Participants receiving single dose of Zavegepant 10 mg
Study NCT05300464 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clinical investigation medical device class IIa marked CE
Description: Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients are ready for MammoWave exam. The exam will composed of two phases: the acquisition and data processing. During the acquisition that sholud takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
Study NCT04692181 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
Study NCT04692181 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SYN-004, Ribaxamase or Placebo
Description: SYN-004 is an oral formulation of a recombinant class-A beta-lactamase that hydrolyzes the beta-lactam ring of susceptible antibiotics that are excreted into the intestines
Study NCT04680260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients will be offered adjuvant chemotherapy according to standard of care. Follow up will be performed with imaging according to standard guidelines, equal to the experimental arm. Blood samples will be analyzed retrospectively to evaluate the ctDNA status.
Study NCT04680260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA guided treatment approach
Description: Circulating tumor-marker positivity will lead to escalation with 6 months of intensified chemotherapy consisting of 4 months of FOLFOXIRI followed by 2 months of 5FU monotherapy. Circulating tumor-marker negativity will based on shared decision-making lead to de-escalation i.e. possibilities for observation in patients otherwise eligible for monotherapy or observation/monotherapy in patients, otherwise eligible for combination chemotherapy according to standard of care.
Study NCT05747313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Phase Ib:~The dose of vincristine administered in this phase is 40 mg on days 1,3,5 of each cycle.~The timepoint for chidamide dosing in this phase is twice weekly, i.e., dosing on days 1,4,8,11,15,18 of each cycle. Take 30 minutes after a meal.~Phase II:~This phase is based on the MTD/RP2D determined in phase I. The phase II expansion group study was conducted. Vincristine is administered at a dose of 40 mg on days 1,3,5 of each cycle. Chidamide was administered at a dose of MTD/RP2D twice a week on days 1,4,8,11,15 and 18 of each cycle. It is to be taken 30 minutes after a meal.
Study NCT05377346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placement of the i-gel
Description: The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
Study NCT05377346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placement of the i-gel
Description: The lubricated i-gel is inserted into the mouth and introduced along the hard palate with a continuous and gentle push until resistance was felt in the hypopharynx.
Study NCT06429852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The DeST-ACT Trauma-Focused Acceptance and Commitment Therapy Program
Description: The Trauma-focused psychosocial intervention program consists of 4 sessions online therapy.
Study NCT06173596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Participants will receive ALXN2080 orally.
Study NCT06173596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive Itraconazole orally.
Study NCT06173596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole (AxMP)
Description: Participants will receive Fluconazole orally.
Study NCT06173596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine (AxMP)
Description: Participants will receive Carbamazepine orally.
Study NCT05981534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 4000IU/day vitamin D supplement will be used for 6 months
Study NCT05981534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used for 6 months
Study NCT06064825 — intervention group
Intervention type: OTHER
Intervention: 2 year follow-up of neurodevelopment using a parental questionnaire
Description: A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
Study NCT04582734 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Description: Cognitive-behavioural therapy intervention
Study NCT06266273 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05686759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Undiluted I.V.-Hepabig inj(GC5103)
Description: undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
Study NCT05686759 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diluted I.V.-Hepabig inj(GC5103)
Description: Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit
Study NCT05646745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Transobturator Fascia Lata Sling
Description: Hydro-distention of the anterior vaginal wall, and a midline incision is made based on the mid-urethra. Dissection is carried out bilaterally to the obturator Foramen on both sides.~Through incision in the lower lateral aspect of the thigh, 4 cm above the knee, \~1 cm× \~5 cm fascial strip is isolated from the fascia lata. Two stay sutures are secured to the corners of the fascial segment on each side.~About 1cm skin incision is performed at the thigh fold on each side. Next, two separate trocar passages are performed on each side using a reusable C-shaped trocar, with care taken to ensure at least a 1 cm tissue bridge in the obturator membrane between the superior and inferior passes. Following this, the stay sutures are tied external to the obturator membrane on both sides, leaving the sling secured and flush with the mid-urethra. Sutures are also placed to secure the sling to the periurethral tissue to prevent rolling or migration of the fascial strip.
Study NCT04995120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy TP regimen combined with Toripalimab
Description: Induction chemotherapy TP regimen combined with Toripalimab for 3 cycles: Toripalimab 240mg d1, Paclitaxel 175mg/m2 d2 or Nab-Paclitaxel 260mg/m2 d2，Cisplatin 25mg/m2 d2-4 q3w.~Response rate of primary tumor is evaluated using laryngoscopy and head and neck MRI after 3 cycles of induction therapy. If overall response rate of primary tumor is complete response or partial response, then chemoradiation is conducted, followed by maintenance therapy of Toripalimab for 8 cycles (6 months). Otherwise, surgery is conducted (laryngeal preservation surgery is preferred), followed by adjuvant radiation/chemoradiation and then maintenance therapy of Toripalimab for 8 cycles.
Study NCT05248984 — intervention group
Intervention type: DRUG
Intervention: Ketorolac
Description: Once the decision has been made by the primary obstetrics (OB) provider to proceed with cesarean delivery, participants will be randomized in to one of two groups:~* Single dose of intravenous (IV) Ketorolac 30mg Vs.~* Single dose of intravenous (IV) Ketorolac 60mg
Study NCT06015581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workforce Development: Tailored Motivational Interviewing and Technical Assistance
Description: TMI training includes an initial 12 hour virtual workshop, standard patient interaction with feedback, group coaching, and a final standard patient interaction and feedback. TMI relies on experiential activities developed by the network while minimizing didactic presentations. Stigma-reducing communication is emphasized by practicing autonomy supportive and empathic statements and improving cultural humility practices. Role plays map on to the Mystery Shopper domains focusing on risk reduction counseling and PrEP referral. TA addresses factors in the EPIS framework.